VivoSeq
Immunology

Chronic Granulomatous Disease

35

Pipeline Programs↗

9

Active Trials↗

17

Companies Involved↗

Chronic Granulomatous Disease is a moderately active landscape with 35 programs across 17 companies. The most active players are Genzyme, a Sanofi Company, Takeda, Amgen. 3 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

55/100

Pipeline Velocity

0/100

Mech. Concentration

13/100

Completion Rate

63/100

Attrition Rate

22/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

G

Genzyme, a Sanofi Company

2 programs

Phase 1Takeda logo

Takeda

1 program

Phase 1Amgen logo

Amgen

1 program

Phase 1J

Jasper Therapeutics, Inc.

1 program

Phase 1P

Prism Pharmaceuticals

1 program

Phase 1Roche logo

Roche

2 programs

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

69%

Small molecule

25 of 36 classified programs — the dominant modality here.

31%ALL OTHERSMonoclonal antibody411%Gene therapy38%Protein / enzyme26%Cell therapy26%

Small molecule leads; the ring shows all 36 classified programs, each share of the total. Modality classified for 98% of 43 pipeline programs.

Analysis

Trial Status

27

clinical trials

Completed10 · 37%
Terminated5 · 19%
Recruiting4 · 15%
Active, not recruiting3 · 11%
Unknown status2 · 7%
Enrolling by invitation2 · 7%
Other1 · 4%

Clinical Trials

Trial Activity

27 trials

Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT05463133·50 enrolled
Fecal Microbiota Transplantation for Chronic Granulomatous Disease-Associated Colitis
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT05333471·20 enrolled
NADPH Oxidase Correction in mRNA Transfected Granulocyte-enriched Cells in Chronic Granulomatous Disease (CGD)
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT05189925·25 enrolled
Lentiviral Gene Therapy for Chronic Granulomatous Disease (CGD)
Recruiting·SShenzhen Geno-Immune Medical Institute·Preclinical·NCT03645486·10 enrolled
Study to Assess the Use of JSP191 in Matched Unrelated Donor Transplantation for Chronic Granulomatous Disease (CGD)
Active, not recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT05600907·7 enrolled
A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants With p47phox Autosomal Recessive Chronic Granulomatous Disease (CGD )
Active, not recruiting·PPrime Medicine, Inc.·Phase 1/2·NCT06559176·12 enrolled
Haploidentical Transplant for Patients With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide
Active, not recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT03910452·4 enrolled
pCCLCHIM-p47 (Lentiviral Vector Transduced CD34 Plus Cells) in Patients With p47 Autosomal Recessive Chronic Granulomatous Disease (AR-CGD)
Enrolling by invitation·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT06253507·10 enrolled
Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory Complications
Enrolling by invitation·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT05104723·20 enrolled
Role of Interferon-gamma 1-b (IFN-γ) on Cells of the Innate Immune System: Functional, Biochemical and Gene Expression Studies in Patients With Chronic Granulomatous Disease
Completed·UUniversity of Colorado, Denver·N/A·NCT03548818·9 enrolled
Gene Therapy for Chronic Granulomatous Diseases - Long-term Follow-up
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00001476·14 enrolled
Pharmacokinetics of Posaconazole in Children With Chronic Granulomatous Disease (CGD)
Completed·RRadboud University Medical Center·Phase 2·NCT00799071·12 enrolled
IL-1 Receptor Inhibitor for Granulomatous Complications in Patients With Chronic Granulomatous Disease
Completed·FFederal Research Institute of Pediatric Hematology, Oncology and Immunology·Phase 1·NCT04136028·13 enrolled
Itraconazole for the Prevention of Fungal Infections in Chronic Granulomatous Disease
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001280·100 enrolled
A Phase IV Study of Recombinant Human Gamma Interferon in Patients With Chronic Granulomatous Diseases of Childhood
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 4·NCT00001317·100 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)